Geode Capital Management LLC Buys 59,732 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Geode Capital Management LLC raised its position in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 46.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 188,408 shares of the company's stock after purchasing an additional 59,732 shares during the quarter. Geode Capital Management LLC owned approximately 0.73% of Contineum Therapeutics worth $2,761,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in CTNM. State Street Corp increased its position in shares of Contineum Therapeutics by 23.7% during the third quarter. State Street Corp now owns 113,566 shares of the company's stock worth $2,174,000 after buying an additional 21,760 shares during the period. Barclays PLC boosted its position in Contineum Therapeutics by 248.6% during the third quarter. Barclays PLC now owns 8,308 shares of the company's stock valued at $158,000 after acquiring an additional 5,925 shares during the last quarter. Franklin Resources Inc. grew its holdings in Contineum Therapeutics by 130.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,447,550 shares of the company's stock worth $27,706,000 after acquiring an additional 820,542 shares during the period. Rhumbline Advisers raised its position in shares of Contineum Therapeutics by 36.3% in the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company's stock worth $121,000 after acquiring an additional 2,191 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Contineum Therapeutics by 32.3% in the 4th quarter. Bank of New York Mellon Corp now owns 18,738 shares of the company's stock valued at $275,000 after purchasing an additional 4,573 shares during the period.

Contineum Therapeutics Trading Up 3.3 %

Shares of CTNM stock traded up $0.13 during trading on Friday, reaching $4.10. 148,359 shares of the company's stock traded hands, compared to its average volume of 79,333. Contineum Therapeutics, Inc. has a 1 year low of $3.69 and a 1 year high of $22.00. The company has a market capitalization of $106.08 million and a P/E ratio of -0.84. The firm's 50-day moving average is $5.89 and its 200 day moving average is $10.80.

Wall Street Analysts Forecast Growth

CTNM has been the subject of several research analyst reports. Morgan Stanley reaffirmed an "overweight" rating and issued a $25.00 price target on shares of Contineum Therapeutics in a research note on Friday, March 7th. Jones Trading started coverage on Contineum Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $23.00 target price on the stock. Robert W. Baird decreased their price objective on shares of Contineum Therapeutics from $32.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $31.00 price target on shares of Contineum Therapeutics in a research report on Thursday, January 9th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Contineum Therapeutics currently has a consensus rating of "Buy" and an average target price of $23.75.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).